M edication prescribing deficiencies are the most common cause of actual and potential adverse drug events. 1±3 Factors related to prescribing errors include:
inadequate drug therapy knowledge; inadequate consideration of patient characteristics; dose calculations; nomenclature; and dosage formulation. 4 Detailed understanding of these contributing factors is useful in designing and implementing improvements in the medication use system. 4±6 Medication dosage formulation is an important method of improving the utility of pharmacologic agents. 7, 8 Common goals of medication dosage form design include: improving drug bioavailability; allowing administration via alternative routes; providing``delayed'' or``sustained'' drug delivery; improving patient convenience; facilitating use in different indications; facilitating use in special populations (such as pediatrics); and facilitating final dose preparation processes. As a result, many medications are available in a number of different dosage forms and dose sizes. While substantial patient benefit and convenience are achieved through the proper use of available medication dosage formulations, inappropriate use of dosage forms poses risk to the patient. 9±45 We have previously reported that prescribing errors involving medication dosage forms accounted for more than 10% of all errors detected in a long-standing medication errors detection and prevention program. 4±7,10,46,47 The risk of such prescribing errors is compounded by the substantial deficiency in the understanding of medication dosage formulation issues by many health care professionals. 11±14 The ever-growing number and complexity of available medication dose formulations are likely to result in growing risk to patients. 9 Considering the available evidence, 4, 6 ,9±47 it appears that the risk to patients from errors involving medication dosage forms is under-appreciated, under-reported, and poorly understood. Increased awareness and improved understanding of the nature of such errors will be useful in the design and implementation of error reduction initiatives. The purpose of this study was to characterize prescribing errors involving or related to medication dosage forms.
METHODS

Identification of Medication Prescribing Errors
The study was conducted in a 631-bed tertiary care teaching hospital located in northeastern New York State. Medication prescribing error data used for study analysis were collected over the period of January 1, 1996 to December 31, 2000, as previously described.
4±6,46,47 All medication orders either written by or cosigned by a credentialed prescriber during the study period were included in the analysis. Medication orders were handwritten or in the form of preprinted order sets. Copies of the original orders were sent to the pharmacy via facsimile or via pneumatic tube. All medication orders were reviewed and entered into the pharmacy computer system by staff pharmacists prior to dispensing. Staff pharmacists routinely utilized all available information resources to evaluate medication orders for appropriateness. Following the identification of medication orders potentially in error, the pharmacist contacted the prescriber or a cross-covering provider to obtain additional information and to discuss the orders in question. Potential prescribing problems were defined as medication orders that involved: the wrong patient, drug, dose, dosing frequency, route of administration, or dosage form; inappropriate indication for use; inappropriate combinations of drugs; documented allergies to ordered medications; contraindicated therapy; missing critical information; and other miscellaneous problems.
The medication order(s) in question were either confirmed as correct as written, or were clarified, changed, or discontinued following the discussion between the pharmacist and the physician. All identified problem orders that were jointly determined by the physician and the pharmacist to require a``correction'' and that were subsequently changed were considered to be``confirmed problem orders.'' All confirmed medication prescribing problems were further reviewed by a clinical pharmacist within 24 hours and by the author within 72 hours. This secondary review was to ensure that the proper actions were taken and to assure provision of appropriate therapy. Problem orders that were determined by the secondary review to be in error were then defined as``confirmed medication prescribing errors.'' The significance of each error was determined based on the general potential of the error to be carried out, and if carried out as ordered, to result in adverse consequences, either an increased risk of adverse effects or an inadequate therapeutic response. Orders that were unlikely to be carried out because of product characteristics, physical and mechanical factors, or the drug distribution and preparation processes of the hospital, etc., were not considered significant. Assessment of the potential adverse outcome of each error was based on available patient and pharmacologic information regarding the risk for adverse events. The potential significance of errant orders was evaluated using a previously described rating scale, and rated as either``Potentially Fatal or Severe,'' Potentially Serious,'' or``Potentially Significant. ' Errors related to dosage forms were defined as those in which there was an order for the inappropriate use of a specific dosage form, an order for the wrong dosage form (errors of commission), or the failure to specify the correct dosage form when more than 1 dose form is commonly available (error of omission). A classification schema for dosage form errors was developed based on evaluation of errors prior to September 1, 1999 (Table 1 ). All prescribing errors involving dosage formulation issues classified as at least``clinically significant,'' i.e., either``potentially fatal/ severe,''``potentially serious,'' or``potentially significant'' were included in this study.
All``clinically significant'' medication prescribing errors involving medication dosage forms detected between January 1, 1996 and December 31, 2000 were used to determine trends in annual number of detected dosage form±related prescribing errors. Errors detected between September 1, 1999 and December 31, 2000 were evaluated in detail to provide a current assessment of medications involved, type of error, and the nature and severity of potential adverse effects had the order been carried out.
RESULTS
Frequency of Errors
A total of 1,115 confirmed``clinically significant'' medication prescribing errors involving or related to medication dosage formulation were detected during the years 1996 to 2000. The total number of detected errors, and number of errors per 100 admissions and number per 1,000 new medication orders detected increased annually over this period (Fig. 1 ). Four hundred two confirmed`c linically significant'' medication prescribing errors involving medication dosage forms were detected and averted from September 1, 1999 to December 31, 2000. These 402 errors were further evaluated for current determination of error characteristics, medications involved and potential for adverse outcomes. During these 16 months, errors were detected at a rate of 1.23 per 100 admissions, 1.84 per 1,000 patient days and 0.61 per 1,000 new medication orders.
Error Types and Medications Involved
Of the 402 errors detected between September 1, 1999 and December 31, 2000, the most common types of errors were: failure to specify controlled release formulation (total 280 cases; 69.7%), which included prescribing using the brand name (148 cases; 36.8%) and using the generic name (132 cases; 32.8%); prescribing controlled delivery formulations to be administered per tube (48 cases; 11.9%); and prescribing controlled delivery dosage forms to be administered``as needed'' when either a continuous`a round the clock'' effect was indicated or the more rapid onset of effect from a noncontrolled delivery formulation was appropriate (30 cases; 7.5%). Table 1 lists the frequency of each type of error detected.
Errors most commonly involved cardiovascular agents (208 cases; 51.7%), antidiabetic agents (39 cases; 9.7%), narcotic analgesics (37 cases; 9.2%), psychiatric medications (34 cases; 8.5%), and xanthines (29 cases; 7.2%). Table 2 lists the number of errors detected by specific medication involved and by medication class.
Potential Adverse Events
The most common potential adverse events, had the orders been carried out, were increased expected drug effects or side effects early in a dosing interval (shortly after drug administration) and/or ineffective therapy at the end of a dosing interval (316 of 402 cases; 78.5%). In 60 cases (15%), the error had the potential to result in ineffective or less-effective therapy only, and in 26 cases (6.5%), a potential for``non±dose-related'' toxic effects existed.
The potential for adverse patient outcome was rated as potentially``fatal/severe'' in 3 cases (0.7%),``serious'' in 49 cases (12.2%), and``significant'' in 350 cases (87.1%). Potentially fatal/severe or serious errors were most commonly caused by failure to specify appropriate dosage form (total of 32 of 52 cases; 61.5%), primarily when the brand name was used (27 cases; 51.9%), and failure to specify unique dosage form with significant bioavailability differences (12 cases 23.1%). Table 1 lists the number of errors rated as severe or serious for each type of dosage form prescribing error. Table 2 lists the number of severe or serious errors for each medication class and specific medication. The most common medications involved in this tragic case, a misinterpreted prescription for benzathine penicillin led to a 10-fold error in preparation and dispensing, which led to the erroneous intravenous administration of a large volume of benzathine penicillin suspension to a newborn child. An additional possible limitation to the generalizability of this study is that long-term pharmacy-based error prevention programs, such as that used, may actually increase the number and/or alter the type of errors detected, as prescribers rely on the system to catch errors and therefore are less concerned about the correctness of their prescriptions. However, the practices at the study hospital are similar to those in many U.S. hospitals, and the errors detected by our processes are consistent with published case reports 9±45 and with those reported to the Institute for Safe Medication Practices (available at: www.ismp.org.org). Thus, the errors reported in this study are likely to be representative of errors occurring in other teaching hospitals without prescriber computer order entry. The underlying factors related to dosage form errors include: inadequate caregiver and patient knowledge and understanding; availability of and difficulty differentiating between multiple dose formulations; confusing and inconsistent nomenclature; inadequate attention to safety concerns in drug preparation and packaging design; product marketing; and inadequate health care system processes to safeguard patients. Given the many contributors to these errors, systems implemented to protect patients from potential risks must be multifaceted as well.
Formal education of health care providers and patients regarding the properties, availability, and proper use of the various medication dosage forms marketed is inadequate. Cohen 15 reported that 35% of nurse anesthetists were unable to name the proper route of administration of longacting injectable penicillin preparations. The inadequacy of training and resulting lack of appreciation for the importance of dosage formulation appeared to contribute to a number of detected errors, such as ordering controlled delivery agents on an``as needed'' basis, ordering controlled delivery forms to be crushed or given per tube, and failing to specify the appropriate dosage form when prescribing. Inclusion of basic information regarding the role of dose formulation issues in pharmacology and therapeutics courses for active and in-training prescribers, nurses, and pharmacists is necessary. As new agents or new dosage forms of previously marketed agents become available, health care organizations,``pharmacy and therapeutics'' committees, and providers must consider the role, value, and potential risks of such products. The nomenclature used for dosage forms is inconsistent and confusing. Terminology varies for individual drugs, within drug classes, or from one manufacturer to another. Adding suffixes to established names of medications (e.g., Cardizem CD, Depakote ER, Wellbutrin SR) is common. This practice results in a lack of clear definition of different formulation properties, and the common problem of omitting the suffix when prescribing. Interestingly, some medications were more commonly found to be prescribed by their brand name, omitting the suffix (bupropion, 13 of 13 occurrences; insulin, 32 of 35 occurrences; nifedipine, 37 of 39 occurrences; venlafaxine, 13 of 15 occurrences), whereas others were found to be more commonly prescribed as generic drugs without specifying the appropriate dosage form (cyclosporine, 12 of 12 occurrences; isosorbide mononitrate, 26 of 30 occurrences; theophylline, 30 of 30 occurrences; verapamil, 22 of 27 occurrences). It is likely that this reflects the frequency with which these drugs are referred to or thought of by brand or generic name, and the impact of marketing of specific agents. Compounding this problem is the failure of pharmaceutical firms to adequately address safety issues related to dose formulation in packaging and marketing of products. For example, controlled-delivery formulations are often available in dose sizes that are simple multiples of the immediate-release form. This practice increases the likelihood that standardrelease forms could be used to provide a controlled-release± sized dose (e.g., nifedipine is available in 10-and 20-mg standard-release forms, and 30-, 60-, and 90-mg sustained-release forms). Considering the large number of agents now available for which suffixes denote special dose forms, any value this practice has in terms of convenience, simplification, and product identification, recognition, and differentiation, is minimal. Use of suffixes in the naming of medications may now be causing so much confusion, and possibly patient harm, that the pharmaceutical industry and FDA should consider a moratorium on the practice until a full risk assessment can be performed. At a minimum, to reduce risk, the simple practice of providing sustained-release forms in dose amounts that are not simple multiples of other dosage forms should be strongly considered. The use of unique names for special formulations (i.e., Neoral, Tiazac, Covera HS) might also reduce risk for error in prescribing by brand name. However, since specific``brands'' of an agent may not be available in all health care settings, a strong chance for confusion still exists. Establishing an improved method of selecting and approving drug names and formulation designations may reduce the frequency of dose formulation±related errors and confusion. Pharmaceutical firms and the U.S. Food and Drug Administration are urged to formally and systematically address dosage form issues in their drug naming and design processes. 49, 50 Improving the medication safety processes within health care generally and, where appropriate, those specifically related to dose formulation issues is necessary to the reduction of risk for adverse drug events from these types of errors.
1±4,6,51,52 Automated processes including prescriber computer order entry, computer-generated medication administration records, and bar code reconciliation of medication dispensing and administration could significantly reduce errors related to dose formulation. 53 Control of access to medications through safe hospital formulary, purchasing, dispensing, distribution, storage, and drug stock removal processes can prevent errors simply by making a medication unavailable or available only in limited circumstances. 51, 52 This study also demonstrates the critical importance pharmacist review of medication orders prior to administration of medication, as stipulated by the Joint Commission on Accreditation of Healthcare Organization standards. 54 Further, improved pharmaceutical decision support through incorporation of pharmacists in patient care has been identified as an effective method to improve prescribing and reduce risk for adverse drug events in general, and would likely improve the prescribing and use of dose formulations.
3,51,55
CONCLUSIONS
Prescribing errors involving dosage formulations are common, and without appropriate safety processes such as pharmacist order review in place, present significant risk to patients. The increasing use and availability of unique dosage forms may account for the increasing number of errors detected over the 5-year study period. The finding of recurring errors of similar type supports the concept that prescribing errors are associated with identifiable factors, which provides opportunity for targeted improvements in the process of medication use. Improvements in health care provider knowledge, dosage form safety design, improved nomenclature, and improvements in medication use system processes are necessary for safeguarding patients from errors involving medication dosage formulation.
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